Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy

Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy

Abstract Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently...

Full description

Bibliographic Details
Main Authors:	Marrium Sultan Dar, Nayab Shahid, Arisha Waqas, Yumna Arif Baig, Aimen Waqar Khan
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Health Science Reports
Subjects:	dabrafenib pediatric low‐grade glioma pLGG trametinib
Online Access:	https://doi.org/10.1002/hsr2.1841

Similar Items

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
by: Alia Thawer, et al.
Published: (2021-09-01)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01)

Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by: Baptiste Le Calvez, et al.
Published: (2020-07-01)

Ocular side effects of Trametinib and Dabrafenib: a case report
by: Bilge Tarım, et al.
Published: (2023-04-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
by: Gil Awada, et al.
Published: (2020-09-01)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
by: Nora Isberner, et al.
Published: (2022-09-01)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
by: Marilda Mormando, et al.
Published: (2020-07-01)

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients
by: Xue Peng, et al.
Published: (2023-01-01)

[Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market]
by: Lorenzo Pradelli, et al.
Published: (2016-12-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
by: Walid Shalata, et al.
Published: (2023-02-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
by: Carola Berking, et al.
Published: (2023-09-01)

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
by: Maria Chiara Tronconi, et al.
Published: (2022-05-01)

Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era
by: Neevika Manoharan, et al.
Published: (2023-02-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
by: Cornelis M. van Tilburg, et al.
Published: (2024-01-01)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
by: Victoria G. Atkinson, et al.
Published: (2021-05-01)

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
by: Ji Eun Shin, et al.
Published: (2022-11-01)

Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
by: Yang Yang, et al.
Published: (2021-12-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

Pediatric low-grade glioma models: advances and ongoing challenges
by: Griselda Metta Yvone, et al.
Published: (2024-01-01)

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report
by: Fang R, et al.
Published: (2024-01-01)

Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF V600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis
by: Eriko Nakamura, et al.
Published: (2024-01-01)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022-04-01)

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
by: Quaglino P, et al.
Published: (2023-11-01)

Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib–trametinib: a case report
by: M. C. Martín-Soberón, et al.
Published: (2021-03-01)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
by: Michele Del Vecchio, et al.
Published: (2023-03-01)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review
by: Ruoxin Fang, et al.
Published: (2023-07-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyResearch in context
by: Xue Bai, et al.
Published: (2023-11-01)

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
by: Gudrun Piringer, et al.
Published: (2023-05-01)

Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression
by: Huimin Zhang, et al.
Published: (2024-04-01)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with <em>BRAF</em> V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
by: Jean-Bernard Auliac, et al.
Published: (2020-12-01)

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
by: Yoshihiko Taniguchi, et al.
Published: (2023-05-01)